
NYSEHealthcareMedical - Devices
Latest quote
$368.75
−$8.22 · -2.18%
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Latest quote
$368.75
−$8.22 · -2.18%
Regular session · ET · Market data may be delayed.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
64
Undervalued
Sentiment
66
Bullish
Risk
36
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.58B USD | 2.57B USD | 2.67B USD | 2.8B USD | 2.92B USD |
| Cost of goods sold | 1.24B USD | 1.19B USD | 1.24B USD | 1.23B USD | 1.28B USD |
| Gross profit | 1.34B USD | 1.38B USD | 1.43B USD | 1.57B USD | 1.64B USD |
| Research and development | 256.9M USD | 295.9M USD | 247.43M USD | 256.89M USD | 260.64M USD |
| Selling, general, and administrative | 819.9M USD | 814M USD | 841.7M USD | 827.83M USD | 877.12M USD |
| Operating expenses | 1.08B USD | 1.11B USD | 1.09B USD | 1.08B USD | 1.14B USD |
| Interest income | 95.5M USD | 82M USD | 100.9M USD | 58M USD | 18.9M USD |
| Interest expense | 49M USD | 48.9M USD | 49.44M USD | 38.11M USD | 1.55M USD |
| Depreciation and amortization | 205.4M USD | 151.6M USD | 145.9M USD | 177.2M USD | 137.6M USD |
| Operating income | 270.5M USD | 269M USD | 337.8M USD | 482.62M USD | 500.34M USD |
| Net income | 759.9M USD | −1.84B USD | −637.32M USD | −3.63B USD | 4.25B USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 8, 2002 | 2:1 | — | — |
Stock split | Jun 3, 1996 | 3:2 | — | — |
Stock split | Jun 11, 1986 | 3:2 | — | — |
Stock split | Aug 1, 1985 | 3:2 | — | — |
Stock split | Mar 18, 1980 | 2:1 | — | — |
Effective Mar 8, 2002
2:1
Effective Jun 3, 1996
3:2
Effective Jun 11, 1986
3:2
Effective Aug 1, 1985
3:2
Effective Mar 18, 1980
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH221.32M0.17%122.69B USD0.05%$73.86-0.94%
Vanguard Morningstar Total Stock Market ETFVTI190.95M0.01%2.3T USD0.03%$373.24-0.62%
Vanguard Morningstar Small-Cap ETFVB138.06M0.07%183.4B USD0.03%$291.18-0.99%
Vanguard Morningstar Small-Cap Value ETFVBR87.66M0.13%68.3B USD0.05%$240.25-0.68%
Vanguard Extended Market ETFVXF67.51M0.07%93.7B USD0.05%$236.16-1.05%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY50.63M0.19%26.09B USD0.23%$673.25-0.94%
Dimensional - US Small Cap Value ETFDFSV45.07M0.54%8.34B USD0.30%$39.54-0.38%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD35.83M0.19%18.41B USD0.03%$64.72-0.95%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
Dimensional - US Small Cap Value ETFDFSV
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.